Aphios Corporation

Company Snapshot

Biotechnology company developing enabling technology platforms and enhanced therapeutic products for preventing and treating certain cancers, infectious diseases, and Central Nervous System (CNS) disorders
Awarded several peer-reviewed, competitive SBIR Grants from NIH and NSF, and ATP grants from the NIST, Department of Commerce
Enabling technology platforms, nanotechnologies and enhanced therapeutic products covered by 36 issued US and international patents, and 22 pending patent applications
History of collaborations with multinational companies such as Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, Baxter Healthcare, Sigma-Aldrich and leading academic institutions

Recent Achievements

Completion of a successful multicenter Phase II/III randomized, placebo-controlled, 644-patient clinical trial of Zindol®, an enhanced ginger product in gel capsules, as an adjunctive therapy for chemotherapy induced nausea and vomiting (CINV)
Nanoencapsulation of siRNA using Aphios' SuperFluids™ CFN technology to improve its delivery and therapeutic efficacy in collaboration with a top five multinational pharmaceutical company

Frost & Sullivan 2009 North American Excellence in Healthcare Technology Innovation of the Year Best Practices Award in the field of Enhanced Nanodrug Therapeutic Systems for SuperFluids™ nanodrug solubility, encapsulation and delivery platforms

Enabling Technology Platforms

Drug Discovery: Patented SuperFluids™ CXF polarity-guided fractionation tech-nology for rapid discovery of drugs from marine microorganisms and medicinal plants
Drug Manufacturing: Patented SuperFluids™ CXP technology for manufacturing natural pharmaceuticals such as paclitaxel, bryostatin 1, betulinic acid, cyclopamine
Drug Delivery: Patented nanotechnologies platforms – Protein Nanoparticles, Phospholipid Nanosomes and Polymer Nanospheres for small molecules, hydro-phobic compounds, siRNA, therapeutic proteins and peptides, and vaccine antigens
Drug Safety: Patented SuperFluids™ CFI pathogen (virus) inactivation for inactivation of both enveloped and nonenveloped virus without damaging proteins

Enhanced Therapeutic Products

Zindol® for chemotherapy induced nausea and vomiting (CINV); APH-0703 for Alzheimer’s Disease and Cognitive Disorders, AMPI-109 is a nanosomal formulation of a nontoxic Vitamin-D derivative for hormone refractory prostate cancer (HRPCA); APH-0701 for HIV Latency; APH-0911 is a Taxotere? prodrug encapsulated in biodegradable polymer nanospheres for cancer chemotherapy or chemoprevention
Infectious disease portfolio includes several anti-influenza, anti-HIV, and anti-smallpox hits, and marine antimicrobial compounds that are effective against plaque and gingivitis and multi-drug resistant human pathogens (MRSA, VRE)
Quality-of-life medicines (nutraceuticals) for emotional well-being, calming stomachs and healthy digestion, and healthy prostate function and hair follicles (US Patents)

Management and Directors